anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
All patients will undergo gait analysis using reflective surface markers placed at different locations on the head, trunk, upper and lower extremities, and pelvis. All patients will complete an analog pain scale, Oswestry, and SRS-22 questionnaires. These are health-related quality of life questionnaires that provide subjective assessment.
BACKGROUND: Purkinje fibers play an important role in initiation and maintenance of ventricular fibrillation (VF) and polymorphic ventricular tachycardia (PMVT). Fascicular substrate modification (FSM) approaches have been suggested to treat recurrent VF in case reports and small case series.
OBJECTIVES: The aim of this study was to investigate outcomes of catheter-based FSM to treat VF and PMVT.
METHODS: Of 2,212 consecutive patients with ventricular arrhythmia undergoing catheter ablation, 18 (0.81%) underwent FSM of the Purkinje fibers as identified with high-density mapping during sinus rhythm. Fascicular substrate and VF initiation were mapped using a multipolar catheter. The endpoint of the ablation was noninducibility of VF and PMVT. In select patients, remapping revealed elimination of the targeted Purkinje potentials. Demographic, clinical, and follow-up characteristics were prospectively collected in our institutional database.
RESULTS: A total of 18 patients (mean age 56 ± 3.8 years, 22% women) were included in the study. Of those, 11 (61.1%) had idiopathic VF, 3 (16.7%) had nonischemic cardiomyopathy, and 4 (22.2%) had mixed cardiomyopathy. The average left ventricular ejection fraction was 42.5%. At least 2 antiarrhythmic drugs had failed preablation. At baseline, all patients had inducible VF or PMVT. At the end of the procedure, no patient demonstrated new evidence of fascicular block or bundle branch block. There were no procedure-related complications. After a median follow-up period of 24 months, 16 patients (88.9%) were arrhythmia free on or off drugs: 11 of 11 patients (100%) with idiopathic VF vs 5 of 7 patients (71.4%) with underlying cardiomyopathy (P = 0.06).
CONCLUSIONS: Catheter ablation of human VF and PMVT with FSM is feasible and safe and appears highly effective, with high rates of acute VF noninducibility and long-term freedom from recurrent VF.
The Prophylactic - Control arm will include subjects who are at transient high risk for PE and do not have diagnosed symptomatic VTE (PE and/or DVT). If randomized into this prophylactic arm, study subjects will receive current best practice PE prevention, namely sequential compression machines, compression stockings, and anticoagulants when indicated. All study subjects will return to the investigation site for the Follow-up Visits at Week 2 (±3 days), Week 10 (±1 week) and Month 9 (±2 weeks). Subjects will be interviewed and examined at each follow-up visit.
FIELD: biotechnology, veterinary science. SUBSTANCE: preparation has bacteria of the starin Bifidobacterium globosum ВГНКИ БФ-4-ДЕП, strain Streptococcus faecium ВГНКИ 27/11-В-ДЕП and combination of virulent polyreceptor staphylococcus bacteriophages. Preparation has aluminium oxide, aluminium hydroxide, carbohydrate and filling agent also. Among staphylococcus strains the preparation has strains ВГНКИ 89/ЦМЭИ-FS-1-ДЕП and ВГНКИ 90/ЦМЭИ-BS-2- ДЕП. Among carbohydrates the preparation can contain lactose and/or sucrose and among filling agents it can contain starch, dry milk, dry whey, whole milk substitute, sugar powder or food sugar. Preparation can contain additionally also dry bacterial mass of acidophilic bacteria and/or dry culture of bacteriophages of pseudomonade strains ВГНКИ 86/ЦМЭИ-AI-ДЕП, ВГНКИ 87/ЦМЭИ-B2-ДЕП, ВГНКИ 88/ЦМЭИ- -C1-ДЕП taken in different combinations. Preparation shows simultaneous prophylactic and curative efficiency in intestine disbacteriosis, it promotes to sanitation of animal intestine from staphylococci and Bacillus pyocyaneus, it shows broad spectrum of antibacterial and phagolytic activity and enhances immune status of animal body. EFFECT: enhanced effectiveness of preparation. 6 cl, 2 tbl, 4 ex
The superior trunk block will be performed at the point immediately distal to the roots when the c5-c6 form the superior trunk and lies anterior to the middle scalene muscle and below the deep cervical fascia, before the suprascapular nerve arises and goes into the omohyoid. A 22g 1.5-2inch needle will be advanced in-plane from lateral to medial. The needle tip will be placed lateral to the superior trunk and 15 20 ml of 0.5% bupivacaine will be injected just inferior to the deep cervical fasica. Local circumferential spread will be achieved both anterior and posterior to the superior trunk.
Computer assisted detection (CAD) is made accessible to more medical offices. The CAD is provided as a service. Customers gain access to CAD service through a computer network but without the purchase of expensive software and/or hardware. The customers use software for extracting (40) needed patient data to use the CAD service. The CAD service provider uses a server farm (18) or third party server facilities, allowing growth without as substantial upfront costs. The CAD service provider collects (52) patient data by providing the service. The aggregated patient data allows training of different or improved CAD algorithms. The service also identifies suspect data, such as associated with incorrect imaging settings, and provides help to the customers.
The invention belongs to the field of biology technology and medicine, and discloses a new human epididymis expression sperm binding protein HEL-128 as well as preparation and application thereof. The invention discloses an amino acid sequence of the proteinHEL-128 protein and provides a recombination expression vector carrying a DNA sequence for coding the protein. The protein is positioned in a back area of the equator of a mature sperm and has expressions in various tissues of the epididymis, the heart, the liver, the spleen, the lung, the kidney, the stomach, the testis and the like, and a band of about 23 KD is detected in the epididymis. Besides, the protein has favorable antibacterial activity and possibly has a specific antibacterial mechanism. The HEL-128 protein can be used as a targeted protein for researching immunity contraceptives, and clinically diagnosing and treating male infertility. A corresponding gene or protein detection method developed based on the HEL-128 protein can be widely applied to the field of reproductive medicine research.
Systems and methods for remote diagnostics and therapies are disclosed. A remote technician or automated computer system, optionally using artificial intelligence algorithms, can communicate with and control home diagnostic and therapeutic devices such as ultrasound imaging devices avoiding the need for patient travel and costly hospital visits. Devices can be delivered via standard courier services or other mechanisms such as drones or self-driving delivery vehicles. Once delivered a remote diagnostic and/or therapy session can be completed using a wired or wireless communications network. Portions of the devices can then be disposed of or returned for redistribution. Devices may include security measures such as user lockouts after authorized use is complete and/or self-destruction mechanisms to prevent tampering or unauthorized use of expensive or proprietary components.
Post-mortem CT (PMCT) scanning was performed on the bodies of two decomposed adult males who had died of natural causes. The bodies both showed changes of marked decomposition with a prominent swelling of tissues on one side of the head compared to the other. A review of police statements confirmed that this matched the positions of the bodies when they were found. Thus, post-mortem hypostasis of putrefactive fluids correlated in both cases with the positions that the bodies had been in when first located. This may be a simple way of identifying or confirming the positions of decomposed bodies after death. It may also assist in indicating whether a body has been moved after putrefactive fluid hypostasis has developed.
PURPOSE: A composition containing L-serine for preventing and treating fatty liver diseases is provided to suppress transcription of SREBP-1(sterol regulatory element-binding protein-1) and accumulation of neutral fat in a liver tissue. CONSTITUTION: A pharmaceutical composition for preventing and treating fatty liver diseases contains L-serine as an active ingredient. The L-serine contains the compound itself or pharmaceutically acceptable salt and solvate. The fatty liver diseases include alcoholic fatty liver, non-alcoholic fatty liver, diabetic fatty liver, or steatohepatitis. A health food for preventing and treating fatty liver diseases contain the L-serine as an active ingredient. The health food includes beverage, gum, vitamin complex, or supplementary food.
The patient received routine care in the hospital until discharge. Three home visits were made to collect the data of patients and caregivers in the 1st and 3rd and 6th months of POP after discharge, but no intervention was made. The visits took about 30-45 minutes.
FIELD: chemistry of polymers. SUBSTANCE: described is method of synthesis of butyl methacrylate-methacrylic acid copolymer binder for transdermal therapeutic systems which comprises from 4.0 to 10.0 wt.% of methacrylic acid has phase vitrification temperatures of 300-305 and 416-420 K by suspension polymerization of monomers in aqueous medium at pH of 3 in the presence of benzoyl peroxide initiator in two stages at 343K for 2 h and at 353K for 2.5 h in the presence of stabilizer, i.e. sodium methacrylate (84 wt.%)-methacrylic acid (16 wt.%) copolymer at initiator concentration of 1.5 wt. %. Method makes it possible to synthesize butyl methacrylate methacrylic acid copolymers which comprise no residual butyl methacrylate monomer since high degree of conversion (99.5-99.8%) is attained during synthesis. EFFECT: more efficient method of synthesis. 2 dwg, 1 ex, 2 tbl
<P>PROBLEM TO BE SOLVED: To provide a method for producing albumin having extremely low levels of or essentially free of colorants, metal ions, human proteins, host proteins, fragments of albumin, polymers or aggregates of albumin and viruses, essentially non-glycated, relatively high free thiol level and having complete C-terminal.  <P>SOLUTION: The process comprises passing albumin through positive mode cation exchange chromatography and then positive mode anion exchange chromatography. Other steps may also be employed, for example ultrafiltration, gel permeation chromatography, affinity chromatography binding the albumin and affinity chromatography binding contaminants. Elution of albumin from a material having no specific affinity for albumin with a compound having affinity for albumin is also disclosed. Ammonium ions are removed in this case by the use of counter ions.  <P>COPYRIGHT: (C)2008,JPO&INPIT
There are 4 periods in this study: 1)screening and washout; 2) Dose Optimization; 3) Dose Maintenance; 4) Safety Follow-up. SPD489 will be used to treat all subjects.
Antipsychotic medications are those that treat the most severe psychiatric symptoms, such as hallucinations, paranoid thoughts, and delusions. Research shows that some of these medications may put people at a higher risk of metabolic derangements, such as insulin resistance. Certain antipsychotics, like clozapine and olanzapine, are associated with a higher risk of metabolic side effects than others, like aripiprazole and ziprasidone. Because people with schizophrenia may experience adverse side effects from switching antipsychotic medications and because it is difficult to find people with schizophrenia who do not have experience taking antipsychotics, this study will use people without psychiatric disorders who are at risk for diabetes in place of people with schizophrenia. The study will compare the effects of single doses of two antipsychotic medications, olanzapine and aripiprazole, on insulin action in this population. In addition to determining metabolic effects of these medications, this study will also seek to demonstrate the feasibility of using mentally healthy people at risk of diabetes as a substitute for people with schizophrenia in studying these effects.

Participation in this study will last 4 weeks. Participants will first complete a screening visit that will include the following: an oral glucose tolerance test (OGTT), which involves a blood draw, consumption of a sugar drink, and then a second blood draw; a review of medical and psychiatric history, including use of medicines and psychiatric medications; and measurement of participants' height and weight. The second visit, scheduled 2 weeks after screening, will include a tracer-clamp study to test how participants' bodies handle sugar. The tracer-clamp study will be conducted over the course of one night and morning and will require participants to stay at the study location overnight. At 3 AM, participants will receive an intravenous line (IV) with a sugar solution. Just before 8 AM, they will receive a second IV in the opposite arm that will draw blood and monitor blood sugar levels.

At 8 AM, participants will begin receiving insulin in the first IV; blood samples will be drawn and blood sugar levels will be monitored during this time to ensure they remain within a healthy range. At 11 AM, participants will receive an injection of an antipsychotic medication into their arm muscles. The antipsychotic, which will be randomly assigned, will be either olanzapine or aripiprazole. Participants will be monitored for 3 hours after receiving the injection of antipsychotic medication; during this time, more blood samples will be drawn, blood sugar levels will be monitored to ensure they are within a healthy range, and secondary medications will be available to counteract certain side effects of the antipsychotics. After 2 more weeks, participants will undergo a third study visit in which they repeat the OGTT.
The test compound was administered as tablets. The Zantrex-3® compound contained yerba maté, caffeine, guarana, damiana, green tea, kola nut, schizonepeta, piper nigrum, ginseng, maca root, and cocoa nut. The content of xantines (caffeine and caffeine-like stimulants) accounted for 365 mg per serving (2 capsules).
Flavanols and their oligomeric derivatives, the procyanidins, are plant-derived compounds normally present in the human diet. Accumulating data demonstrate a causal role for flavanols in mediating the cardiovascular benefits associated with the consumption of flavanol-/procyanidin-containing foods. Evidence for a direct, causal role for procyanidins in this context is far less profound. As this is often based on the poor absorption of procyanidins, it has been proposed that procyanidins may indirectly contribute to the systemic presence of bioactive compounds via derivatives generated from the breakdown or catabolism of procyanidins in the gastrointestinal tract. These postulated 'breakdown products' include: i) flavanols, putatively generated by acid hydrolysis in the stomach, and ii) series of phenolic compounds, including 5-(3,4-dihydroxyphenyl)-gamma-valerolactone, that are produced from procyanidin catabolism by the gut microbiome. Verification or rejection of these suppositions could significantly impact the interpretation of epidemiological-/dietary intervention data, and the design of food-content data bases. To address this question, healthy volunteers will consume specially designed cocoa-based dairy drinks containing flavanols and procyanidins (dimers to decamers) either together or individually.
Acuvail to be given preoperatively. One drop 2 times (BID), 1 day pre op and day of surgery 3 doses prior to surgery.
The survey schedule was planned to be independent of the students' assessment period and the questionnaire was administered to the students when they were attending a lecture together. After the lecture, a researcher explained to the students the purpose of this survey and assured them of confidentiality. Participation in this study was also voluntary, and all participants remained anonymous. The questionnaire was given to all participants after explaining the purpose of the study. The questionnaire included demographic details (age, gender, year of study), social background (parents' education levels, family income, first choice for admission, living accommodation) and lifestyle behaviors (smoking status, presence of regular sport activity and hobby). In addition, Warwick-Edinburg Mental Well-Being Scale was applied to the participants of this study.
Group 3 innate lymphoid cells (ILC3s) regulate inflammation and tissue repair at mucosal sites, but whether these functions pertain to other tissues-like the kidneys-remains unclear. Here, we observed that renal fibrosis in humans was associated with increased ILC3s in the kidneys and blood. In mice, we showed that CXCR6+ ILC3s rapidly migrated from the intestinal mucosa and accumulated in the kidney via CXCL16 released from the injured tubules. Within the fibrotic kidney, ILC3s increased the expression of programmed cell death-1 (PD-1) and subsequent IL-17A production to directly activate myofibroblasts and fibrotic niche formation. ILC3 expression of PD-1 inhibited IL-23R endocytosis and consequently amplified the JAK2/STAT3/RORγt/IL-17A pathway that was essential for the pro-fibrogenic effect of ILC3s. Thus, we reveal a hitherto unrecognized migration pathway of ILC3s from the intestine to the kidney and the PD-1-dependent function of ILC3s in promoting renal fibrosis.
The rapidly increasing prevalence of obesity and overweight, especially in children and adolescents, has become a serious societal issue. Although various genetic and environmental risk factors for pediatric obesity and overweight have been identified, the problem has not been solved. In this study, we examined whether environmental nanoplastic (NP) pollutants can act as environmental obesogens using mouse models exposed to NPs derived from polystyrene and polypropylene, which are abundant in the environment. We found abnormal weight gain in the progeny until 6 weeks of age following the oral administration of NPs to the mother during gestation and lactation. Through a series of experiments involving multi-omic analyses, we have demonstrated that NP-induced weight gain is caused by alterations in the lipid composition (lysophosphatidylcholine/phosphatidylcholine ratio) of maternal breast milk and he gut microbiota distribution of the progeny. These data indicate that environmental NPs can act as obesogens in childhood.
A cohort of patients who previously received baclofen and canceled the course due to the development of side effects and/or individual intolerance, or who have contraindications to the use of this drug, will receive several injections with a total volume of 100 units. botulinum toxin type "A" in dilution up to 20 ml, distributed at the trigger points of the pelvic floor muscles.
Epithelial ovarian cancer (EOC) is the most lethal type of gynaecological cancer, due to lack of effective screening possibilities and because the disease tends to metastasize before onset of symptoms. Women with an increased inherited risk for EOC are advised to undergo a risk-reducing salpingo-oophorectomy (RRSO), which decreases their EOC risk by 96% when performed within guideline ages. However, it also induces premature menopause, which has harmful consequences. There is compelling evidence that the majority of EOCs originate in the fallopian tube. Therefore, a risk-reducing salpingectomy with delayed oophorectomy (RRS with DO) has gained interest as an alternative strategy. Previous studies have shown that this alternative strategy has a positive effect on menopause-related quality of life and sexual health when compared to the standard RRSO. It is hypothesized that the alternative strategy is non-inferior to the standard RRSO with respect to oncological safety (EOC incidence). Three prospective studies are currently including patients to compare the safety and/or quality of life of the two distinct strategies. In this article we discuss the background, opportunities, and challenges of the current and alternative strategy.
INTRODUCTION: The cardiovascular (CV) safety of testosterone (T) replacement therapy (TRT) is still conflicting. Recent data suggested a TRT-related increased risk of atrial fibrillation (AF). The aim of this study was to systematic review and meta-analyze CV risk related to TRT as derived from placebo controlled randomized trials (RCTs).
AREAS COVERED: An extensive Medline, Embase, and Cochrane search was performed. All placebo-controlled RCTs reporting data on TRT-related CV safety were considered. To better analyze the role of T on AF, population-based studies investigating the relationship between endogenous circulating T levels and AF incidence were also included and analyzed.
EXPERT OPINION: Out of 3.615, 106 studies were considered, including 8.126 subjects treated with TRT and 7.310 patients allocated to placebo. No difference between TRT and placebo was observed when major adverse CV events were considered. Whereas the incidence of non-fatal arrhythmias and AF was increased in the only trial considering CV safety as the primary endpoint, this was not confirmed when all other studies were considered (MH-OR 1.61[0.84;3.08] and 1.44[0.46;4.46]). Similarly, no relationship between endogenous T levels and AF incidence was observed after the adjustment for confounders Available data confirm that TRT is safe and it is not related to an increased CV risk.
Grade 3 impaired wound healing was reported in 2 patients (0.3%) treated with ZALTRAP/FOLFIRI regimen.

Withhold ZALTRAP for at least 4 weeks prior to elective surgery. Do not administer ZALTRAP for at least 4 weeks after major surgery and until wounds have adequately healed. For minor surgery such as central venous access port placement, biopsy, and tooth extraction, ZALTRAP may be initiated/resumed once the surgical wound is fully healed. Discontinue ZALTRAP in patients with impaired wound healing. The safety of resumption of ZALTRAP after resolution of wound healing complications has not been established [see Dosage and Administration (2.2)].
Cardiac glucosides are converted into their acid esters by treatment with a halide or oxyhalide of a polybasic inorganic acid, preferably in the presence of an acid-binding agent.  Their salts, which are water-soluble, are useful therapeutically. Examples are given of the treatment of digitoxin and G-strophanthin (ouabain) with phosphorus oxychloride in dry pyridine and the conversion of the resulting phosphoric esters into their sodium salts.  The samples furnished under Sect. 2 (5) comprise (1) the sodium salt of oleandrin phosphoric ester prepared by reacting oleandrin with phosphorus oxychloride in pyridine and converting into the sodium salt, and (2) G-strophanthin sulphuric acid ester sodium salt obtained by treating G-strophanthin with chlorosulphonic acid in pyridine and chloroform and forming the sodium salt.  The Specification as open to inspection under Sect. 91 also refers to the use of a halide or oxyhalide of an organic acid.  This subject-matter does not appear in the Specification as accepted.